Businessweek

DARA BioSciences, Inc, Q1 2013 Earnings Call, May 16, 2013

On May 13, 2013, DARA BioSciences, Inc received a notification letter from the Listing Qualifications Department of The NASDAQ Stock Market (NASDAQ) indicating that, for the last 30 consecutive business days, the bid price for the company’s common stock has closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Marketplace Rule 5550(a)(2). In accordance with Marketplace Rule 5550(a)(2), the company has 180 calendar days, or until November 11, 2013, to regain compliance with the minimum $1.00 price per share requirement. To regain compliance, anytime before November 11, 2013, the bid price of the company’s common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days. NASDAQ’s notification letter has no effect on the listing of the company’s common stock at this time. On November 11, 2013, if the company meets The Nasdaq Capital Market initial listing criteria set forth in Marketplace Rule 5505, except for the minimum bid price requirement, it may be provided with an additional 180 calendar day compliance period to demonstrate compliance. If the company is not eligible for an additional compliance period at that time, NASDAQ will provide the company with written notification that its common stock will be delisted. Upon such notice, the company may appeal the NASDAQ Staff’s determination to a Nasdaq Listing Qualifications Panel pursuant to the procedures set forth in the applicable NASDAQ Marketplace Rules. There can be no assurance that, if the company appeals the NASDAQ Staff’s determination, such appeal would be successful. The company is currently evaluating its alternatives to resolve this listing deficiency.

On May 10, 2013, DARA BioSciences Inc. held its 2013 Annual Meeting of Stockholders. The company ratified the appointment of Horne, LLP as the company's independent registered public accounting firm for 2013.

DARA BioSciences Inc. announced that DARA has reintroduced Gelclair(R) into the U.S. market. Gelclair is manufactured by the Helsinn Group and is an FDA-cleared product indicated for the treatment of oral mucositis. Oral mucositis is a painful inflammation and ulceration of the surface of the mouth and throat, which can result from a variety of cancer treatments, including radiation therapy and chemotherapy. Gelclair provides oral mucositis patients rapid and effective relief of pain. Oral mucositis is common in cancer patients undergoing chemotherapy or radiation therapy and occurs when the protective oral mucosa is denuded, potentially resulting in pain, infection, weight loss, decreased quality of life, treatment delay and increased economic costs.

DARA BioSciences, Inc Presents at 2013 BIO International Convention, Apr-23-2013 08:30 AM. Venue: McCormick Place - Chicago Bulls Room, 2301 S. Lake Shore Drive, Chicago, IL 60616, United States.